SK Biopharm reported Q1 2026 operating profit of $62M, a 249.7% surge year-over-year, according to a regulatory filing on May 7.
Financial Highlights
Both Q1 2026 revenue and operating profit significantly exceeded prior-year and prior-quarter results. Operating margin came in at 39.4%.
- Revenue: $157M, +57.8% YoY, +17.2% QoQ
- Operating Profit: $62M, +249.7% YoY, +94.0% QoQ
- Net Income: $71M, +423.5% YoY
- Net Income Attributable to Parent: $72M, +351.2% YoY
Market Reaction
The stock rallied following earnings, according to media reports. Press coverage identified U.S. market expansion of Xcopri (cenobamate), SK Biopharm's epilepsy therapeutic, as the key driver of accelerating results. However, analysts flagged concerns: Yonhap Infomax and pharmacist trade publications noted the absence of visible pipeline candidates and warned that expanded R&D spending could become a drag on future profitability. Hit News reported annual revenue has crossed the $480M threshold.
This article was auto-generated from regulatory filings and press reports for timely dissemination of key data. Please consult official company disclosures before making trading decisions.
